Education
About Us
Working with TipRanks
Follow Us
CSL Limited (CSLLY)
OTHER OTC:CSLLY
CSLLY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$70.06 - $104.87
Previous CloseN/A
Volume10.38K
Average Volume (3M)4.03K
Market Cap
$75.70B
Enterprise Value$38.23B
Total Cash (Recent Filing)$1.52B
Total Debt (Recent Filing)$11.96B
Price to Earnings (P/E)27.3
Beta0.46
Next Earnings
Aug 19, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 11, 2025Dividend Yield1.55%
Share Statistics
EPS (TTM)2.07
Shares Outstanding968,424,260
10 Day Avg. Volume0
30 Day Avg. Volume4,028
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)6.55
Price to Sales (P/S)0.00
P/FCF Ratio97.41
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue0.66
Enterprise Value/Gross Profit5.20
Enterprise Value/Ebitda2.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CSL News
PremiumCompany Announcements
CSL Limited Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
CSL Limited Reports Strong Half-Year Financial Performance
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
CSLLY FAQ
What was CSL Limited’s price range in the past 12 months?
CSL Limited lowest stock price was $70.06 and its highest was $104.87 in the past 12 months.
What is CSL Limited’s market cap?
CSL Limited’s market cap is $75.70B.
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Aug 19, 2025 which is in 52 days.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Feb 11, 2025. The company reported $2.074 earnings per share for the quarter, beating the consensus estimate of N/A by $2.074.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Overvalued.
Does CSL Limited pay dividends?
CSL Limited pays a Semiannually dividend of $0.6 which represents an annual dividend yield of 1.55%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CSL Limited have?
CSL Limited has 968,424,260 shares outstanding.
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of $2.074 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.486%.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in CSLLY
CSL Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 33.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.72%
12-Months-Change
Fundamentals
Return on Equity
15.36%
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited (CSLLY) is a global biotechnology company focused on the development and delivery of innovative medicines that save lives and improve quality of life. The company operates in the biotechnology sector and primarily focuses on developing therapies for people with rare and serious diseases. CSL's core products include plasma-derived therapies and vaccines, with key areas of operation including immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. With a strong commitment to research and development, CSL has a pipeline of potential new medicines in various stages of clinical trials.
CSLLY Company Deck
CSLLY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of CSL's financial performance. Strong growth in CSL Behring and CSL Vifor, along with successful regulatory milestones, were offset by challenges in CSL Seqirus due to declining vaccination rates and increased competition in Europe. Overall, the call reflects a stable performance with a positive outlook for revenue growth.Read More>